Amal Therapeutics receives CTI grant to evaluate immunotherapy combination treatments

Geneva, Switzerland, March 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced that it received a grant from the Swiss Commission for Technology & Innovation (CTI) to validate immunotherapies combination treatments.